Tran Van Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tran Van Bao has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Le Thi Thanh Thuy
Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
3 shared publications - Hoang Hai
Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
2 shared publications - Nguyen Bui Tam Chi
Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
2 shared publications - Pham Tuan Anh
Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
2 shared publications Daisuke Oikawa
Department of Medical Biochemistry, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
1 shared publication- Dang Minh Quang
Sarcoma Center, Vinmec Times City, Vinmec International Hospital, Hanoi, Vietnam
1 shared publication
Latest Publications
- Open Access
Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma
Background: Osteosarcoma remains the most common primary malignant bone tumor in children and adolescents, with largely unchanged survival outcomes in recent decades. Non-invasive biomarkers for preoperative risk stratification are urgently needed. Circulating immune checkpoint proteins (ICPs) and bone remodeling factors (BRFs) represent promising candidates; however, their combined prognostic value in osteosarcoma remains unclear. Methods: We prospectively analyzed plasma samples from 47 patients with osteosarcoma, selecting the earliest available sample before disease progression or the last follow-up. A panel of ICPs and BRFs was quantified using multiplex immunoassays. sHVEM and sCD27 were used to construct a two-marker ICP signature (ICP2); subtypes were defined by unsupervised consensus clustering (k = 2) applied to log2-transformed sHVEM and sCD27 concentrations, and sOPN was included for integrative analysis. Survival associations were assessed using Kaplan–Meier analysis and Firth’s penalized Cox regression. The model performance was evaluated using Harrell’s C-index. Results: Two ICP2 subtypes were identified (type1, n = 26; type2, n = 21). ICP2-type2 was associated with significantly worse progression free survival (PFS) (p = 0.0045) and overall survival (OS) (p = 0.0024) and remained an independent predictor after adjusting clinicopathological factors. The ICP2 model demonstrated high discriminative performance (C-index 0.924 for PFS and 0.903 for OS). Internal validation by leave-one-out cross-validation (LOOCV), in which consensus clustering was re-derived at each fold, yielded corrected C-indices of 0.612 for PFS and 0.806 for OS (versus apparent estimates of 0.687 and 0.689, respectively), confirming acceptable-to-good discrimination after accounting for overfitting. Elevated sOPN was associated with poorer survival in the exploratory analyses, although its prognostic value was less consistent under a pre-specified cutoff. In the combined models, sOPN provided modest additional value for OS stratification, with the grdgfdgICP2-type2/OPN-high subgroup exhibiting the poorest outcome. Conclusions: The circulating sHVEM/sCD27 signature defines prognostically distinct osteosarcoma subtypes with a strong discriminative performance. This minimally invasive model may support preoperative risk stratification. Integration with sOPN suggests a potential biological link between immune regulation and bone remodeling, warranting validation in larger cohorts.
Open AccessIntegration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma
Background: Osteosarcoma remains the most common primary malignant bone tumor in children and adolescents, with largely unchanged survival outcomes in recent decades. Non-invasive biomarkers for preoperative risk stratification are urgently needed. Circulating immune checkpoint proteins (ICPs) and bone remodeling factors (BRFs) represent promising candidates; however, their combined prognostic value in osteosarcoma remains unclear. Methods: We prospectively analyzed plasma samples from 47 patients with osteosarcoma, selecting the earliest available sample before disease progression or the last follow-up. A panel of ICPs and BRFs was quantified using multiplex immunoassays. sHVEM and sCD27 were used to construct a two-marker ICP signature (ICP2); subtypes were defined by unsupervised consensus clustering (k = 2) applied to log2-transformed sHVEM and sCD27 concentrations, and sOPN was included for integrative analysis. Survival associations were assessed using Kaplan–Meier analysis and Firth’s penalized Cox regression. The model performance was evaluated using Harrell’s C-index. Results: Two ICP2 subtypes were identified (type1, n = 26; type2, n = 21). ICP2-type2 was associated with significantly worse progression free survival (PFS) (p = 0.0045) and overall survival (OS) (p = 0.0024) and remained an independent predictor after adjusting clinicopathological factors. The ICP2 model demonstrated high discriminative performance (C-index 0.924 for PFS and 0.903 for OS). Internal validation by leave-one-out cross-validation (LOOCV), in which consensus clustering was re-derived at each fold, yielded corrected C-indices of 0.612 for PFS and 0.806 for OS (versus apparent estimates of 0.687 and 0.689, respectively), confirming acceptable-to-good discrimination after accounting for overfitting. Elevated sOPN was associated with poorer survival in the exploratory analyses, although its prognostic value was less consistent under a pre-specified cutoff. In the combined models, sOPN provided modest additional value for OS stratification, with the grdgfdgICP2-type2/OPN-high subgroup exhibiting the poorest outcome. Conclusions: The circulating sHVEM/sCD27 signature defines prognostically distinct osteosarcoma subtypes with a strong discriminative performance. This minimally invasive model may support preoperative risk stratification. Integration with sOPN suggests a potential biological link between immune regulation and bone remodeling, warranting validation in larger cohorts.
- Open Access
- 30 April 2026
- Published by Hue University of Medicine and Pharmacy in Tạp chí Y Dược Huế
- Vol. 16 (02) , 133-140
Clinical and histopathological characteristics of soft tissue tumours at Hue University of Medicine and Pharmacy Hospital
Background: Soft tissue tumors represent a relatively common and heterogeneous group of lesions characterized by diverse yet nonspecific clinical manifestations. Although histopathology remains the diagnostic gold standard, the application of advanced techniques such as immunohistochemistry is indispensable to ensure the accurate diagnosis with the latest WHO classification. Objectives: (1) To describe clinical characteristics and the histopathological classification of soft tissue tumors. (2) To evaluate the expression of immunohistochemical markers in soft tissue tumors. Materials and methods: A cross-sectional study was conducted on 166 patients diagnosed with soft tissue t umors between 04/2025 and 01/2026 at Hue University of Medicine and Pharmacy Hospital. Results: Malignant soft tissue tumors accounted for 21.1% of cases. The majority presented with a single lesion (91.6%), most commonly located in the superficial trunk (34.4%). Tumors smaller than 5 cm comprised 68.1% of cases. Adipocytic tumors were the most frequent (42.8%). Lipoma and hemangioma were predominant in the benign group (53,4% and 15,5%), fibrohistiocytoma in the borderline group (61,5%), and fibrosarcoma in the malignant group (22,7%). Immunohistochemistry revealed the expression of characteristic markers that supported the diagnostic classification, Vimentine (+) 100%, Desmine (+) 5/5 cases and SMA (+) 3/5 cases for smooth tumours, CD68 (+) 100% for fibrohistiocytic tumours, CD34 (+) for vascular and the other tumours.. Conclusion: Malignant soft tissue tumors accounted for 21.1% of cases. Besides histopathology, immunohistochemistry revealed the expression of characteristic markers that supported the key role for the classification of tumour types. Keywords: soft tissue tumours, histopathology, clinical characteristics, immunohistochemistry
- 30 April 2026
- Published by Hue University of Medicine and Pharmacy in Tạp chí Y Dược Huế
- Vol. 16 (02) , 133-140
Open AccessClinical and histopathological characteristics of soft tissue tumours at Hue University of Medicine and Pharmacy Hospital
Background: Soft tissue tumors represent a relatively common and heterogeneous group of lesions characterized by diverse yet nonspecific clinical manifestations. Although histopathology remains the diagnostic gold standard, the application of advanced techniques such as immunohistochemistry is indispensable to ensure the accurate diagnosis with the latest WHO classification. Objectives: (1) To describe clinical characteristics and the histopathological classification of soft tissue tumors. (2) To evaluate the expression of immunohistochemical markers in soft tissue tumors. Materials and methods: A cross-sectional study was conducted on 166 patients diagnosed with soft tissue t umors between 04/2025 and 01/2026 at Hue University of Medicine and Pharmacy Hospital. Results: Malignant soft tissue tumors accounted for 21.1% of cases. The majority presented with a single lesion (91.6%), most commonly located in the superficial trunk (34.4%). Tumors smaller than 5 cm comprised 68.1% of cases. Adipocytic tumors were the most frequent (42.8%). Lipoma and hemangioma were predominant in the benign group (53,4% and 15,5%), fibrohistiocytoma in the borderline group (61,5%), and fibrosarcoma in the malignant group (22,7%). Immunohistochemistry revealed the expression of characteristic markers that supported the diagnostic classification, Vimentine (+) 100%, Desmine (+) 5/5 cases and SMA (+) 3/5 cases for smooth tumours, CD68 (+) 100% for fibrohistiocytic tumours, CD34 (+) for vascular and the other tumours.. Conclusion: Malignant soft tissue tumors accounted for 21.1% of cases. Besides histopathology, immunohistochemistry revealed the expression of characteristic markers that supported the key role for the classification of tumour types. Keywords: soft tissue tumours, histopathology, clinical characteristics, immunohistochemistry
- Open Access
- 14 April 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 485
Therapeutic Potential of Cytoglobin and Neuroglobin in Oxidative Stress-Driven Liver Diseases
Chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), are primarily driven by oxidative stress, yet traditional antioxidant therapies often lack the specificity and efficacy required for clinical success. This review evaluates the emerging therapeutic potential of two atypical globins, cytoglobin (CYGB) and neuroglobin (NGB), exploring their unique hexacoordinated heme structures that enable potent reactive oxygen and nitrogen species (ROS/RNS) scavenging and redox-regulated signaling. We summarize a broad range of in vitro and in vivo evidence demonstrating that these globins deactivate hepatic stellate cells, reduce extracellular matrix accumulation, and function as tumor suppressors by modulating pathways such as Raf/MEK/ERK and NRF2. In human cohorts, CYGB expression levels inversely correlate with the progression of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and HCC, highlighting its potential as a clinical biomarker. Furthermore, recombinant protein therapies involving CYGB and NGB show promise in promoting collagen degradation and inhibiting malignant transformation. We conclude that CYGB and NGB represent sophisticated catalytic redox regulators that offer a novel therapeutic paradigm for restoring redox homeostasis. While delivery and pharmacokinetic barriers remain, these globins are highly promising candidates for first-in-class biologics in hepatology.
- 14 April 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 485
Open AccessTherapeutic Potential of Cytoglobin and Neuroglobin in Oxidative Stress-Driven Liver Diseases
Chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), are primarily driven by oxidative stress, yet traditional antioxidant therapies often lack the specificity and efficacy required for clinical success. This review evaluates the emerging therapeutic potential of two atypical globins, cytoglobin (CYGB) and neuroglobin (NGB), exploring their unique hexacoordinated heme structures that enable potent reactive oxygen and nitrogen species (ROS/RNS) scavenging and redox-regulated signaling. We summarize a broad range of in vitro and in vivo evidence demonstrating that these globins deactivate hepatic stellate cells, reduce extracellular matrix accumulation, and function as tumor suppressors by modulating pathways such as Raf/MEK/ERK and NRF2. In human cohorts, CYGB expression levels inversely correlate with the progression of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and HCC, highlighting its potential as a clinical biomarker. Furthermore, recombinant protein therapies involving CYGB and NGB show promise in promoting collagen degradation and inhibiting malignant transformation. We conclude that CYGB and NGB represent sophisticated catalytic redox regulators that offer a novel therapeutic paradigm for restoring redox homeostasis. While delivery and pharmacokinetic barriers remain, these globins are highly promising candidates for first-in-class biologics in hepatology.
- Open Access
- 11 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (5) , 101783
Single-cell fixed RNA profiling uncovers SEMA4D and LMCD1 as therapeutic targets in a liver fibrosis model
- 11 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (5) , 101783
Open AccessSingle-cell fixed RNA profiling uncovers SEMA4D and LMCD1 as therapeutic targets in a liver fibrosis model